Norwegian Ultimovacs has made some big announcements recently, including discussions for a fifth phase II clinical trial with universal cancer vaccine UV1, a private placement of 270 MNOK to fund the trial and other projects, plus the FDA’s decision to grant dual Fast Track designation for UV1 in advanced melanoma. To discuss this and more, Ultimovacs’ CEO Carlos de Sousa linked up to the BioStock Studio remotely from Oslo for a Q&A.
Watch the full interview with Carlos de Sousa below.
The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.